Roflumilast
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout Roflumilast
Roflumilast is a phase 3 stage product being developed by AstraZeneca for Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT00073177. Target conditions include Asthma.
What happened to similar drugs?
20 of 20 similar drugs in Asthma were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03381573 | Pre-clinical | Completed |
| NCT02068456 | Pre-clinical | Completed |
| NCT01354782 | Phase 1 | Completed |
| NCT01140542 | Phase 2 | Completed |
| NCT00246935 | Phase 3 | Completed |
| NCT00246922 | Phase 3 | Completed |
| NCT00242294 | Phase 2/3 | Completed |
| NCT00108823 | Phase 3 | Completed |
| NCT00242307 | Phase 2/3 | Completed |
| NCT00163475 | Phase 3 | Completed |
| NCT00076076 | Phase 3 | Completed |
| NCT00076089 | Phase 3 | Completed |
| NCT00073177 | Phase 3 | Completed |
| NCT00062582 | Phase 3 | Completed |
| NCT00163527 | Phase 3 | Completed |
| NCT00430729 | Phase 3 | Completed |
Competing Products
20 competing products in Asthma